VYGR Voyager Therapeutics, Inc.

Nasdaq voyagertherapeutics.com


$ 3.99 $ -0.27 (-6.35 %)    

Thursday, 13-Nov-2025 15:59:58 EST
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 3.98
$ 4.19
$ 3.94 x 100
$ 4.55 x 250
-- - --
$ 2.65 - $ 7.44
457,098
na
221.29M
$ 1.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 03-11-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-06-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-07-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 03-08-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-06-2020 03-31-2020 10-Q
24 03-03-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-09-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 02-26-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-14-2018 12-31-2017 10-K
33 11-02-2017 09-30-2017 10-Q
34 08-08-2017 06-30-2017 10-Q
35 05-09-2017 03-31-2017 10-Q
36 03-15-2017 12-31-2016 10-K
37 11-10-2016 09-30-2016 10-Q
38 08-11-2016 06-30-2016 10-Q
39 05-12-2016 03-31-2016 10-Q
40 03-17-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-voyager-therapeutics-lowers-price-target-to-25

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Voyager Therapeutics (NASDAQ:VYGR) with a Buy and lowers the p...

 voyager-therapeutics-files-for-mixed-shelf-offering-of-up-to-400m

-SEC Filing

 voyager-therapeutics-q3-eps-047-beats-051-estimate-sales-13365m-beat-7858m-estimate

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of ...

 voyager-therapeutics-alzheimers-portfolio-and-alpl-neuroshuttle-underscore-platform-momentum-analyst

Voyager's Alzheimer's programs show longer CNS exposure and potential gene therapy advances, with analysts maintaining ...

 hc-wainwright--co-reiterates-buy-on-voyager-therapeutics-maintains-30-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $...

 wedbush-maintains-outperform-on-voyager-therapeutics-lowers-price-target-to-8

Wedbush analyst Yun Zhong maintains Voyager Therapeutics (NASDAQ:VYGR) with a Outperform and lowers the price target from $9...

 voyager-therapeutics-q2-eps-057-misses-054-estimate-sales-520m-miss-991m-estimate

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate o...

 voyager-therapeutics-introduced-a-wholly-owned-program-that-modulates-the-expression-of-apolipoprotein-e-for-alzheimers-disease

New program combines IV-delivered TRACER capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 va...

 voyager-therapeutics-announces-first-peer-reviewed-publication-of-data-showing-ability-of-alkaline-phosphatase-to-transport-novel-aav-capsid-across-the-blood-brain-barrier

Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseas...

 voyager-therapeutics-q1-eps-053-misses-046-estimate-sales-647m-miss-1356m-estimate

Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate o...

 hc-wainwright--co-reiterates-buy-on-voyager-therapeutics-maintains-30-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 ...

 voyager-unveils-preclinical-data-on-dual-tau-programs-for-alzheimers-ahead-of-adpd-2025

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad b...

 canaccord-genuity-maintains-buy-on-voyager-therapeutics-lowers-price-target-to-12

Canaccord Genuity analyst Sumant Kulkarni maintains Voyager Therapeutics (NASDAQ:VYGR) with a Buy and lowers the price targe...

 hc-wainwright--co-reiterates-buy-on-voyager-therapeutics-maintains-30-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION